methyl 2-(5-bromo-2-(chlorosulfonyl)phenyl)acetate | 1403387-05-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(5-bromo-2-(chlorosulfonyl)phenyl)acetate
• 英文别名: Methyl 2-[5-bromo-2-(chlorosulfonyl)phenyl]acetate；methyl 2-(5-bromo-2-chlorosulfonylphenyl)acetate
• CAS: 1403387-05-2
• 化学式: C₉H₈BrClO₄S
• mdl: MFCD28954089
• 分子量: 327.583
• InChiKey: AKAHSAYSSDOQBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P271,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P403+P233,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H314,H335
• 包装等级：
  III

反应信息

• 作为反应物：
  描述：

  methyl 2-(5-bromo-2-(chlorosulfonyl)phenyl)acetate 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 4-bromo-2-(2-hydroxyethyl)-N-(4-methoxybenzyl)benzenesulfonamide
  参考文献：
  名称：

  ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF

  摘要：

  The invention provides novel anilino-pyrazole derivatives as a cyclin-dependent kinase 2 (CDK2) inhibitors. The invention also provides pharmaceutical compositions comprising the compounds and methods thereof for treating various conditions, diseases and disorders associated with or related to CDK2 activities, or associated with abnormal cell growth, such as tumor growth and cancer.

  公开号：

  WO2023244710A1
• 作为产物：
  描述：

  2-(3-溴苯基)乙酸甲酯 在 氯磺酸 作用下， 以54%的产率得到methyl 2-(5-bromo-2-(chlorosulfonyl)phenyl)acetate
  参考文献：
  名称：

  [EN] PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES
  [FR] COMPOSÉS PYRROLOSULFONAMIDES POUR LA MODULATION DE L'ACTIVITÉ DU RÉCEPTEUR ORPHELIN GAMMA APPARENTÉ AU RÉCEPTEUR NUCLÉAIRE ORPHELIN RAR (ROR-GAMMA, NR1F3) ET POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES CHRONIQUES ET AUTO-IMMUNES

  摘要：

  本发明提供了针对孤儿核受体RORγ的调节剂，以及通过向需要的人类或哺乳动物施用这些新型的RORγ调节剂来治疗RORγ介导的疾病的方法。具体而言，本发明提供了式(1)的吡咯磺酰胺化合物及其对映体、非对映体、互变异构体、溶剂化物和药用可接受的盐。

  公开号：

  WO2012139775A1

文献信息

• [EN] INHIBITORS OF CD40-CD154 BINDING<br/>[FR] INHIBITEURS DE LIAISON CD40-CD154
  申请人：TONIX PHARMACEUTICALS HOLDING CORP

  公开号：WO2020210831A1

  公开（公告）日：2020-10-15

  Disclosed herein are compounds including pharmaceutically acceptable salts, esters, prodrugs, hydrates and tautomers thereof which modulate the interactions of CD-40-CD40L. The compounds are useful for treating, ameliorating or preventing an autoimmune disease, inflammatory disease, or other immune-related disease in a patient in need of treatment.

  本文披露了包括药用可接受的盐、酯、前药、水合物和互变异构体在内的化合物，这些化合物调节CD-40-CD40L的相互作用。这些化合物可用于治疗、改善或预防患有自身免疫疾病、炎症性疾病或其他免疫相关疾病的患者。
• [EN] NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE<br/>[FR] NOUVEAUX DÉRIVÉS SUBSTITUÉS PAR UN 2-INDOLE, COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：PFIZER

  公开号：WO2016147144A1

  公开（公告）日：2016-09-22

  A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The 5 invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also 10 relates to a process for manufacturing compounds of Formula I.

  提供了一种化合物I的化合物：或其药学上可接受的对映体、盐或溶剂。该发明还涉及将化合物I用作TDO2抑制剂。该发明还涉及将化合物I用于治疗和/或预防癌症、帕金森病、阿尔茨海默病和亨廷顿病等神经退行性疾病、慢性病毒感染如HCV和HIV、抑郁症和肥胖症。该发明还涉及一种制造化合物I的方法。
• Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
  申请人：Steeneck Christoph

  公开号：US08946446B2

  公开（公告）日：2015-02-03

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了RORy孤儿核受体的调节剂，并通过向需要该药的人类或哺乳动物施用这些新型RORy调节剂来治疗RORy介导的疾病的方法。具体而言，本发明提供了式（1）及其对映体、二对映体、互变异构体、溶剂化物和药学上可接受的盐的吡咯磺酰胺化合物。
• PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES
  申请人：Steeneck Christoph

  公开号：US20140142082A1

  公开（公告）日：2014-05-22

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

  该发明提供了调节孤儿核受体RORy的调节剂，并通过向需要治疗RORy介导疾病的人类或哺乳动物施用这些新型RORy调节剂的方法进行治疗。具体而言，本发明提供了化合物1的吡咯磺酰胺化合物及其对映体，异构体，互变异构体，溶剂化物和药学上可接受的盐。
• NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
  申请人：Pfizer Inc.

  公开号：US20160272628A1

  公开（公告）日：2016-09-22

  A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.

  本发明提供了一种I式化合物或其药学上可接受的对映体、盐或溶剂的制备方法。本发明还涉及将I式化合物用作TDO2抑制剂的用途。本发明还涉及将I式化合物用于治疗和/或预防癌症、神经退行性疾病，如帕金森病、阿尔茨海默病和亨廷顿病、慢性病毒感染，如HCV和HIV、抑郁症和肥胖症的用途。本发明还涉及一种制造I式化合物的方法。